G'day Jaggin, maybe this is a rose coloured glasses thing but I actually find the disclosure quite positive and in line with the way that Baker carries himself and this company - he's a straight shooter.
First the first time ever in the history of bio-spec companies you have these guys coming out and saying we're not happy with some technical issues associated with the contract research orgs in-mouse trials and that they want the trial to be repeated. Good on them. Good quality control and good science by my read.
Ann: Update on ALA-101 and onCARlytics research collaboration, page-11
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
-0.005(4.17%) |
Mkt cap ! $120.7M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.0¢ | 11.5¢ | $27.61K | 234.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 391488 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 546412 | 11 |
View Market Depth
| Last trade - 15.46pm 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
11.8¢ |
Change
-0.005 ( 2.08 %) |
||||
| Open | High | Low | Volume | ||
| 12.0¢ | 12.0¢ | 11.5¢ | 319349 | ||
| Last updated 15.32pm 27/05/2024 ? | |||||
| ALA (ASX) Chart |